Magnetic Brain Stimulation for Thinking Problems After a Stroke
Tests magnetic brain stimulation against a sham treatment in people with thinking problems after stroke.
Plain-language title generated from the registry record
Registry title: High-Frequency Repetitive Transcranial Magnetic Stimulation for Cognitive Improvement in Patients With Post-Stroke Cognitive Impairment
Key facts
- Where
- Jinan, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 35 and 75 years old?
Source: NCT07546877, who can take part
Where in China
- Qilu Hospital of Shandong UniversityJinan, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Qilu Hospital of Shandong University
- Trial code
- NCT07546877
- Record updated
- 23 April 2026
- Original description
To clarify the clinical efficacy of high-frequency rTMS on patients with post-stroke cognitive impairment, fNIRS and EEG techniques were used to observe the changes in brain functional activities of patients with post-stroke cognitive impairment after rTMS treatment, and to clarify the neuroregulatory effect of rTMS on patients with post-stroke cognitive impairment.Read full original descriptionShow less
Efficacy of High-Frequency Repetitive Transcranial Magnetic Stimulation in Patients With Post-Stroke Cognitive Impairment: A Randomized Controlled Trial
To clarify the clinical efficacy of high-frequency rTMS on patients with post-stroke cognitive impairment, fNIRS and EEG techniques were used to observe the changes in brain functional activities of patients with post-stroke cognitive impairment after rTMS treatment, and to clarify the neuroregulatory effect of rTMS on patients with post-stroke cognitive impairment.
Inclusion: Meets the diagnostic criteria for stroke as stipulated in the "Guidelines for the Prevention and Treatment of Stroke in China (2021 Edition)", and the initial stroke diagnosis is confirmed by cranial CT or MRI examination, and is confirmed as the initial onset; The disease course is 1-12 months; Has cognitive impairment (MoCA < 26 points, education years ≤ 12 years, add 1 point to the score result); Age 35-75 years old, gender not limited; Stable vital signs, no progressive neurological symptoms; No severe aphasia, visual or auditory impairment, and able to complete the research protocol; Not using antidepressant drugs simultaneously; If using cognitive-improving drugs (such as donepezil, memantine), it should last for at least 3 weeks or more, and no dose adjustment will be made during the enrollment period; Voluntarily participate and sign the informed consent form.
Exclusion: Has a history of brain tumors, brain trauma, epilepsy or mental disorders; Had cognitive impairment before the stroke; Had implanted metal or electronic devices (such as cardiac pacemakers, cochlear implants, deep brain stimulators, aneurysm clips, internal fixation devices after ventriculoperitoneal shunt surgery, etc.); Has other serious diseases that may affect the study; Underwent craniotomy or had a skull defect; Pregnant women.